This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

BLACK FRIDAY SAVINGS END IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 15 - 18, 2024
Marriott Marquis San DiegoLive In-Person Event: December 15 - 18, 2024
December 15 - 18, 2024
Marriott Marquis San Diego,
Live In-Person Event: December 15 - 18, 2024

Bispecific and Multispecific Antibody insights

Access speaker interviews, sponsored content, and expert opinion pieces that deliver practical insights and updates on the latest advancements in antibody therapeutics. Stay informed with valuable event resources and discover key trends driving the future of bispecific and multispecific antibody development.

Bispecific and Multispecific Content

Ryan Henrici: Revolutionizing Antibody Design

In this interview, Ryan Henrici shares insights into his transformative work at BigHat Biosciences, where he leads translational research. Ryan discusses his journey from medical and scientific training to the forefront of antibody engineering, motivated by a passion for creating safer and more effective therapies. He highlights how BigHat’s cutting-edge machine learning and synthetic biology platforms streamline antibody discovery and optimization, accelerating breakthroughs in therapeutic design.

Design Meets Biology – Engineering Immune Engagers with Potentially Approved Therapeutic Index

John Schardt, Ph.D., Senior Scientist at AstraZeneca delves into innovative approaches to T cell engagers, focusing on selectively activating virus-specific CD8+ effector memory T cells in the tumor microenvironment. By utilizing DuetMab-guided pMHC staging (GPS) molecules, this talk will highlight strategies to enhance therapeutic index while minimizing toxicity, paving the way for safer cancer immunotherapies.

Alex Lugovskoy: Pioneering Multispecific Antibody Therapeutics

In this insightful interview, Alex Lugovskoy, CEO of Diagonal Therapeutics, shares how his company’s ground breaking DIAGONAL platform is revolutionizing the field of antibody therapeutics. With over two decades of experience in biotechnology, Alex discusses the unique challenges of designing agonist antibodies that restore dysfunctional signalling pathways, particularly in rare and severe diseases. His expertise in leveraging computational and experimental methods to develop life-changing therapies highlights the promise of multispecific antibodies to address the root causes of complex diseases.

Multabodies: Exploiting Avidity and Multi-specificity to Achieve Ultra-potent Biologics

Joanne Hulme will explore the innovative Multabody platform, which enhances antibody potency by leveraging increased valency through avidity and multi-specificity. This talk will highlight how these modular, antibody-based constructs retain favorable pharmacokinetics while delivering potent biotherapeutics. Discover the transformative potential of Multabodies in tackling difficult-to-treat diseases such as cancer and infectious diseases, positioning them as the next generation of therapeutics.

Key Market Stats and Growth Trends for 2024

$7.5bn+

2024 global market value for bispecific antibodies

32.6%

Compound annual growth rate expected for bispecific antibodies through 2030

100+

Clinical trials in progress for bispecific and multispecific antibodies

70%

Share of bispecific antibodies in oncology applications

35%+

Expected annual growth rate for multispecific antibodies by 2030

450%

Projected growth in bispecific market value by 2030, reaching $41bn

15+

New bispecific/multispecific antibody approvals expected by 2025

60+

Countries involved in clinical development and trials for multispecific antibodies

90+

Pharma and biotech companies actively developing bispecific and multispecific antibody platforms

Exploring Bispecific and Multispecific Antibodies: Key Topics at Our Upcoming Event

expand_less

How do bispecific antibodies differ from traditional monoclonal antibodies?

Bispecific antibodies can target two different antigens on different cell types, facilitating a stronger immune response by crosslinking these antigens and activating immune cells like T-cells. Kristel Kemper, Ph.D. (Genmab, The Netherlands) will explain how DuoBody-EpCAMx4-1BB works by targeting EpCAM on tumour cells and 4-1BB on immune cells. By crosslinking these two antigens, it enhances T-cell activation and boosts antitumor responses, which is a hallmark of bispecific antibody function

Michael Kierny

PhD, Scientist I

AstraZeneca

With fascinating presentations from high calibre speakers, the Antibody Engineering conference is essential to understanding the advances in the field.